论文部分内容阅读
为改变小儿急性髓性白血病(AML)的化疗效果及预后还不理想的状况,从1996年到1997年,我们采用中剂量阿糖胞苷治疗了11例小儿AML,取得了较好的疗效。随访时间:9例存活者中最长随访期为26个月,平均19个月,目前均生存良好。我们体会,中剂量Ara-C对于小儿急性髓性白血病确是一种有效的治疗方法,该方案虽然对骨髓有较强的毒性,但一般均能恢复,且其他脏器的毒性作用不明显。在目前小儿AML疗效不理想、而骨髓移植又不能普遍采用的情况下,超常剂量的Ara-C不失为一种有效手段,值得采用。
In order to change the chemotherapy effect and the prognosis of acute myelogenous leukemia (AML) in children, the use of medium dose of cytarabine for treating 11 children with AML from 1996 to 1997 has achieved good results. Follow-up time: The longest follow-up of 9 survivors was 26 months with an average of 19 months, and all survived well at present. We understand that the medium-dose Ara-C is indeed an effective treatment for children with acute myeloid leukemia, although the program has strong toxicity to bone marrow, but generally can recover, and the toxicity of other organs is not obvious. In the current infantile AML is not ideal, and bone marrow transplantation can not be used universally, the extraordinary dose of Ara-C is an effective means, it is worth using.